FOXO4-DRI dose guide

FOXO4-DRI dosage

An experimental senolytic peptide: in mice it selectively triggers the death of "zombie cells" (senescent cells) that build up with age and release inflammatory signals, by disrupting the survival switch they rely on. Commonly reported: fatigue and flu-like malaise on dosing days, and for some better skin or less joint stiffness in the weeks after a run. It has only been studied in mice and cells, with no human safety data, and is used in short, infrequent cycles.

Dose range

1–2 mg (research range). Studied in research — not a recommendation.

How often

3× weekly: 3x/week (short cycles)

A typical run

Very short cycles only — 3x/week for 1–2 weeks, infrequently (1–2x per year). Experimental compound. In mouse research it's studied beside navitoclax (ABT-263), another senolytic, which isn't in this library.

How it’s taken

Vial: SubQ injection

Evidence

Emerging: Primarily preclinical / limited human data

Half-life

Hours

FOXO4-DRI on your syringe

With a 10 mg vial and 2 mL of water (5 mg in every mL), on a 0.5 mL (50-unit) U-100 insulin syringe: the low end, 1 mg, is 20 units; and the high end, 2 mg, is 40 units. 10 doses in the vial at the low end. All U-100: 100 units to the mL. A U-40 syringe reads differently.

FOXO4-DRI in the peptide libraryThe Dose Guide: every peptide

More longevity peptides

• MOTS-c 5–10 mg
• NAD+ 50–100 mg
• Glutathione 100–600 mg
• Epitalon 5–10 mg
• Humanin 2–4 mg
• SS-31 2–4 mg
• Pinealon 100–200 mcg
• Vesugen No reference dose
• Klotho 0.01–0.1 mg
• NMN 250–1000 mg
• SNAP-8 3–10%
• DSIP 200–400 mcg

A community reference, not medical advice. Each range is what has been studied or is commonly run, never a dose for you.